What we know about joint decline — and what medicine hasn't addressed yet

Researchers publishing in the journal Science established a direct, functional connection between the gut microbiome and joint health — involving metabolomic analysis of nearly 2,000 individuals across two independent cohorts. People with osteoarthritis consistently showed lower levels of a bile acid called GUDCA compared to healthy controls. The lower the GUDCA, the more severe the joint disease.

A specific gut bacterium, Clostridium bolteae, produces bile acids including UDCA and GUDCA. These acids act on a receptor in the intestinal lining called FXR, stimulating specialised gut cells to produce GLP-1 — the same signalling molecule now widely discussed for its metabolic effects. This gut-derived GLP-1 travels through the bloodstream to the joints, where GLP-1 receptors are present in joint tissue. There it acts as a biological brake on cartilage degradation.

In people with osteoarthritis, C. bolteae is consistently depleted. So is GUDCA. So is the GLP-1 signal that reaches the joint. The brake is gone — not because the joint itself has failed first, but because the gut environment that sustains it has deteriorated.

The researchers also found that UDCA — an FDA-approved drug already in clinical use for other conditions — was associated with a meaningfully lower risk of joint replacement surgery in a real-world cohort of nearly 6,000 patients. The pathway is not theoretical. It has been validated in human populations.

A separate study published in Nature Communications identified a second critical mechanism operating in joint tissue itself. Researchers identified a protein called SHP that acts as a natural defender of cartilage — suppressing a signalling pathway, IKKβ/NF-κB, that when active drives production of two enzymes, MMP-3 and MMP-13, which physically break down the cartilage matrix.

In healthy joints, SHP keeps this pathway quiet. In osteoarthritis patients, SHP levels decline as the disease progresses — accelerating the very destruction it was preventing. Restoring SHP in animal models reduced cartilage damage and improved joint function.

The IKKβ/NF-κB pathway that SHP suppresses is also activated by bacterial byproducts that enter the bloodstream when the gut barrier is compromised. Gut dysbiosis leads to a leaky gut, inflammatory molecules enter circulation, NF-κB activates, SHP is suppressed, and cartilage-destroying enzymes increase. The gut is upstream of both pathways.

A 2026 review in Nature Reviews Rheumatology synthesised the emerging evidence and confirmed that gut microbiota dysbiosis plays a significant role in osteoarthritis pathogenesis — through impaired gut barrier function, altered hormone secretion, and systemic low-grade inflammation.

It identified probiotics, prebiotics, and dietary interventions as legitimate emerging therapeutic strategies, named next-generation biotics as a key research frontier, and noted plainly that OA treatment has historically focused on pain relief rather than disease modification.

The woman who notices stiffness in her mid-40s, whose GP finds nothing significant on imaging, who is told to exercise and monitor — she is in the window where both mechanisms are quietly deteriorating. Her C. bolteae may already be depleted. Her GUDCA may already be lower than her healthy peers. Her SHP levels may already be declining.

Medicine has no intervention for this window. Not because the biology is not understood — it now is — but because drug development timelines mean clinical tools targeting these pathways are years from reaching patients.

Yang et al. (2025). Gut microbiota–bile acid–GLP-1 axis in osteoarthritis. Science. doi:10.1126/science.adt0548

Kang et al. (2026). SHP protects against osteoarthritis by inhibiting IKKβ/NF-κB-mediated matrix-degrading enzymes in chondrocytes. Nature Communications.

[Author et al.] (2026). The gut–joint axis in osteoarthritis. Nature Reviews Rheumatology. doi:10.1038/s41584-026-01378-2